|
ViNS to boost indigenous plasma protein production with Rs. 150 crore investment in PlasmaGen
|
|
Nandita Vijayasimha, Bengaluru
January 17 , 2026
|
|
|
ViNS Bioproducts has made a strategic Rs. 150 crore investment in Kolar-based PlasmaGen Biosciences, underscoring its commitment to strengthening indigenous production of plasma-derived proteins in India.
The funding aims to support PlasmaGen’s expansion plans, enhance domestic manufacturing capabilities, and reduce the country’s reliance on imported plasma therapeutics while positioning the company for growth in global markets.
The government is playing an enabling role by increasing state funding for plasma product procurement and instituting positive policy interventions such as allowing plasma imports and creating incentives for domestic manufacturers. The current manufacturing capacity for plasma products in India has not been able to keep up with the rapidly growing demand, said Vinod Nahar, founder & managing director, PlasmaGen Biosciences.in an earlier interaction with Pharmabiz.
"We are excited to lead this Rs. 150 crore funding round in PlasmaGen Biosciences, alongside partners like Eight Roads Ventures, valuing this innovative biopharma player at over Rs. 1,500 crore, Siddharth Daga, managing director, ViNS Bioproducts told Pharmabiz in an email.
Our interest stems from PlasmaGen's work in plasma-derived therapies, which perfectly complements ViNS Bio's deep expertise in biologics. As a leader in life-saving proteins, we see immense potential in bridging India's critical plasma therapy gap through self-reliant manufacturing, he added.
In fact, this strategic investment accelerates PlasmaGen's scale-up at their state-of-the-art Kolar facility, enabling faster production of essential critical care solutions and seamless global expansion. By partnering with PlasmaGen, we're not just funding growth—we're fostering a robust biopharma ecosystem that prioritizes scalable innovation, specialty therapies, and access across 70+ cities and international markets, noted Daga.
At ViNS Bio, we strategically back high-potential innovators to drive sustainable healthcare advancements. This collaboration amplifies our shared mission, blending our manufacturing prowess with PlasmaGen's vision for transformative plasma proteins. Together, we are poised to deliver impactful solutions worldwide, strengthening India's position in the global biopharma landscape, said Daga.
While efforts to connect with Plasmagen spokesperson was in vain for this particular fund infusion development of Rs. 150 crore from ViNS, a media report stated,” PlasmaGen has raised more than Rs. 600 crore to date and sells products such as albumin, intravenous immunoglobulin, and rabies immunoglobulin to private hospitals and state governments across more than 70 Indian cities. The company also recently bolstered its senior leadership, appointing a new chief operating officer for manufacturing and a chief financial officer ahead of its next phase of growth.”
Plasma-derived therapies, used to treat immune deficiencies, liver disease, bleeding disorders, and certain infections, are considered critical but supply-constrained medicines in India. Limited domestic fractionation capacity has historically made the country dependent on imports, keeping costs high and availability uneven.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|